ARS Pharmaceuticals (SPRY) Expected to Announce Quarterly Earnings on Monday

ARS Pharmaceuticals (NASDAQ:SPRY) is expected to announce its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $25.5840 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, March 9, 2026 at 8:30 AM ET.

ARS Pharmaceuticals Stock Performance

NASDAQ SPRY opened at $8.87 on Wednesday. The firm’s 50 day simple moving average is $10.33 and its 200 day simple moving average is $10.21. The firm has a market capitalization of $876.80 million, a price-to-earnings ratio of -10.95 and a beta of 0.78. The company has a current ratio of 6.66, a quick ratio of 6.51 and a debt-to-equity ratio of 1.14. ARS Pharmaceuticals has a 1 year low of $6.66 and a 1 year high of $18.90.

Analyst Ratings Changes

A number of brokerages have weighed in on SPRY. Roth Mkm initiated coverage on ARS Pharmaceuticals in a report on Tuesday, November 4th. They issued a “buy” rating and a $30.00 target price on the stock. Zacks Research raised ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research note on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $30.67.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in SPRY. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in ARS Pharmaceuticals by 3.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,994 shares of the company’s stock worth $596,000 after purchasing an additional 1,234 shares during the period. FAS Wealth Partners Inc. boosted its holdings in shares of ARS Pharmaceuticals by 0.9% during the 4th quarter. FAS Wealth Partners Inc. now owns 202,407 shares of the company’s stock worth $2,358,000 after buying an additional 1,787 shares in the last quarter. Osaic Holdings Inc. boosted its holdings in shares of ARS Pharmaceuticals by 52.8% during the 2nd quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock worth $91,000 after buying an additional 1,803 shares in the last quarter. Cresset Asset Management LLC increased its stake in shares of ARS Pharmaceuticals by 6.7% in the 2nd quarter. Cresset Asset Management LLC now owns 30,152 shares of the company’s stock valued at $526,000 after acquiring an additional 1,900 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in shares of ARS Pharmaceuticals by 58.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,097 shares of the company’s stock valued at $106,000 after acquiring an additional 2,245 shares during the period. 68.16% of the stock is owned by institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.